Copyright © 2010 Floyd A. Beckford. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. G. Sava, S. Pacor, A. Bergamo, M. Cocchietto, G. Mestroni, and E. Alessio, “Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition,” Chemico-Biological Interactions, vol. 95, no. 1-2, pp. 109–126, 1995. View at Publisher · View at Google Scholar · View at Scopus
2. G. Sava and A. Bergamo, “Ruthenium-based compounds and tumour growth control (review),” International Journal of Oncology, vol. 17, no. 2, pp. 353–365, 2000. View at Scopus
3. J. M. Rademaker-Lakhai, D. van den Bongard, D. Pluim, J. H. Beijnen, and J. H. Schellens, “A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent,” Clinical Cancer Research, vol. 10, no. 11, pp. 3717–3727, 2004. View at Publisher · View at Google Scholar · View at PubMed
4. G. Sava, R. Gagliardi, A. Bergamo, E. Alessio, and G. Mestroni, “Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine,” Anticancer Research, vol. 19, no. 2, pp. 969–972, 1999. View at Scopus
5. A. Bergamo, B. Gava, E. Alessio, et al., “Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity,” International Journal of Oncology, vol. 21, no. 6, pp. 1331–1338, 2002. View at Scopus
6. C. G. Hartinger, S. Zorbas-Seifried, M. A. Jakupec, B. Kynast, H. Zorbas, and B. K. Keppler, “From bench to bedside—preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1$H$-indazole)ruthenate(III)] (KP1019 or FFC14A),” Journal of Inorganic Biochemistry, vol. 100, no. 5-6, pp. 891–904, 2006. View at Publisher · View at Google Scholar · View at PubMed
7. S. Kapitza, M. Pongratz, M. A. Jakupec, et al., “Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells,” Journal of Cancer Research and Clinical Oncology, vol. 131, no. 2, pp. 101–110, 2005. View at Publisher · View at Google Scholar · View at PubMed
8. E. D. Kreuser, B. K. Keppler, W. E. Berdel, A. Piest, and E. Thiel, “Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines,” Seminars in Oncology, vol. 19, no. 2, supplement 3, pp. 73–81, 1992.
9. R. E. Morris, R. E. Aird, P. Murdoch, et al., “Inhibition of cancer cell growth by ruthenium(II) arene complexes,” Journal of Medicinal Chemistry, vol. 44, no. 22, pp. 3616–3621, 2001. View at Publisher · View at Google Scholar
10. O. Novakova, J. Kasparkova, V. Bursova, et al., “Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA binding proteins and repair. Relationship to cytotoxicity,” Chemistry & Biology, vol. 12, no. 1, pp. 121–129, 2005.
11. A. Casini, A. Guerri, C. Gabbiani, and L. Messori, “Biophysical characterization of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies,” Journal of Inorganic Biochemistry, vol. 108, no. 5-6, pp. 995–1006, 2002.
12. J. Will, A. Kyas, W. S. Sheldrick, and D. Wolters, “Identification of (${\eta }^6$-arene)ruthenium(II) protein binding sites in E. coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of [(${\eta }^6$-$p$-cymene)${\text{RuCl}}_2$(DMSO)] to stress-regulated proteins and to helicases,” Journal of Biological Inorganic Chemistry, vol. 12, no. 6, pp. 883–894, 2007.
13. A. Casini, G. Mastrobuoni, M. Terenghi, et al., “Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome $c$,” Journal of Biological Inorganic Chemistry, vol. 12, no. 8, pp. 1107–1117, 2007. View at Publisher · View at Google Scholar · View at PubMed
14. A. Casini, C. Gabbiani, E. Michelucci, et al., “Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound,” Journal of Biological Inorganic Chemistry, vol. 14, no. 5, pp. 761–770, 2009. View at Publisher · View at Google Scholar · View at PubMed
15. P. A. Zunszain, J. Ghuman, T. Komatsu, E. Tsuchida, and S. Curry, “Crystal structural analysis of human serum albumin complexed with hemin and fatty acid,” BMC Structural Biology, vol. 3, article 6, 2003. View at Publisher · View at Google Scholar · View at PubMed
16. B. Honore, “Conformational changes in human serum albumin induced by ligand binding,” Pharmacology and Toxicology, vol. 66, supplement 2, pp. 7–26, 1990.
17. F. A. Beckford, G. Leblanc, J. Thessing, et al., “Organometallic ruthenium complexes with thiosemicarbazone ligands: synthesis, structure and cytotoxicity of [(${\eta }^6$-$p$-cymene)Ru(NS)${\text{CI}]}^{+}$ (NS = 9-anthraldehyde thiosemicarbazones),” Inorganic Chemistry Communications, vol. 12, no. 11, pp. 1094–1098, 2009. View at Publisher · View at Google Scholar · View at PubMed
18. S. Krimm and J. Bandekar, “Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins,” Advances in Protein Chemistry, vol. 38, pp. 181–364, 1986.
19. J.-S. Mandeville, E. Froehlich, and H. A. Tajmir-Riahi, “Study of curcumin and genistein interactions with human serum albumin,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 2, pp. 468–474, 2009. View at Publisher · View at Google Scholar · View at PubMed
20. J. R. Lakowicz and J. G. Weber, “Quenching of fluorescence by oxygen. Probe for structural fluctuations in macromolecules,” Biochemistry, vol. 12, no. 21, pp. 4161–4170, 1973. View at Publisher · View at Google Scholar
21. W. R. Ware, “Oxygen quenching of fluorescence in solution: an experimental study of the diffusion process,” The Journal of Physical Chemistry, vol. 66, no. 3, pp. 455–458, 1962. View at Publisher · View at Google Scholar
22. S.-S. Wu, W.-B. Yuan, H.-Y. Wang, Q. Zhang, M. Liu, and K.-B. Yu, “Synthesis, crystal structure and interaction with DNA and HSA of (N,$N^{\prime }$-dibenzylethane-1,2-diamine) transition metal complexes,” Journal of Inorganic Biochemistry, vol. 102, no. 11, pp. 2026–2034, 2008. View at Publisher · View at Google Scholar · View at PubMed
23. S. S. Aleksenko, C. G. Hartinger, O. Semenova, K. Meelich, A. R. Timerbaev, and B. K. Keppler, “Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis,” Journal of Chromatography A, vol. 1155, no. 2, pp. 218–221, 2007. View at Publisher · View at Google Scholar · View at PubMed
24. P. D. Ross and S. Subramanian, “Thermodynamics of protein association reactions: forces contributing to stability,” Biochemistry, vol. 20, no. 11, pp. 3096–3102, 1981.
25. O. Novakova, H. Chen, O. Vrana, A. Rodger, P. J. Sadler, and V. Brabec, “DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free medial,” Biochemistry, vol. 42, no. 39, pp. 11544–11554, 2003. View at Publisher · View at Google Scholar · View at PubMed
26. D. M. Byler and H. Susi, “Examination of the secondary structure of proteins by deconvolved FTIR spectra,” Biopolymers, vol. 25, no. 3, pp. 469–487, 1986.